Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
When stomach cancer comes back after treatment, families often search for one simple answer: Which medication can treat it now?
Unfortunately, recurrent stomach cancer does not have one standard medication that works for everyone. Treatment depends on where the cancer has returned, whether it has spread, what treatments have already been given and what biological characteristics are found in the tumor.
This is why two patients with recurrent gastric cancer may receive completely different medicines.
Biomarker testing is particularly important. Depending on the situation, doctors may look at HER2, PD-L1, MSI/MMR and CLDN18.2, among other characteristics. These results can help determine whether a targeted medicine or immunotherapy is appropriate.
Key Takeaways |
|
Which Medications are Used When Stomach Cancer Comes Back?
For advanced or recurrent gastric cancer, medication may include chemotherapy, targeted therapy and immunotherapy. The choice often depends on what was used during the first treatment and whether the cancer responded or progressed.
Common systemic treatment approaches include chemotherapy drugs such as paclitaxel, docetaxel and irinotecan, as well as targeted medicines such as ramucirumab and HER2-directed therapies.
The National Cancer Institute lists chemotherapy, targeted treatment and immunotherapy among treatment approaches used for advanced or recurrent gastric cancer.
Importantly, not every drug is specifically approved as a "recurrence medication." Some are approved for advanced or metastatic disease, which may include patients whose cancer has recurred and become unresectable or metastatic.
Your oncologist therefore needs to match the medicine to your exact treatment situation.
Is Ramucirumab Approved for Recurrent Stomach Cancer?
Yes. Ramucirumab (Cyramza) is one of the established targeted medicines used in advanced gastric and gastroesophageal junction adenocarcinoma.
The U.S. FDA approved ramucirumab as a single agent for advanced or metastatic gastric or GEJ adenocarcinoma that has progressed during or after prior fluoropyrimidine- or platinum-containing chemotherapy. It is also approved in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
This makes ramucirumab particularly relevant to the discussion of recurrent disease.
However, the fact that it is approved does not mean every patient should receive it. Previous treatment, performance status, bleeding risk and other clinical factors need to be considered.
For some patients, ramucirumab plus paclitaxel may be discussed as a second-line treatment. Others may require a different approach because of previous treatment or medical circumstances.
Can HER2-Targeted Medications be Used After Stomach Cancer Recurrence?
For patients whose tumors are HER2-positive, HER2-directed treatment can be an important part of the treatment pathway.
One example is trastuzumab deruxtecan (Enhertu). The FDA approved it for adults with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have previously received a trastuzumab-based regimen.
In the DESTINY-Gastric01 study supporting the approval, patients had already received at least two previous treatment regimens, including trastuzumab and chemotherapy. The trial showed longer overall survival and a higher objective response rate with trastuzumab deruxtecan than with physician's-choice irinotecan or paclitaxel.
This is an important example of why HER2 testing should not be overlooked when gastric cancer returns.
The HER2 result can influence both first-line and later-line treatment decisions.
Can Immunotherapy Be Used for Recurrent Stomach Cancer?
Immunotherapy can be part of gastric cancer treatment, but its use depends heavily on the treatment setting and tumor characteristics.
Pembrolizumab (Keytruda) is an important example. The FDA has approved pembrolizumab with chemotherapy for first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.
For HER2-positive disease, the FDA also granted traditional approval in 2025 for pembrolizumab combined with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy in patients whose tumors express PD-L1 with a CPS of at least 1.
This highlights an important point: PD-L1 status can matter when deciding whether immunotherapy belongs in the treatment plan.
MSI-H or dMMR tumors are another important group because immune checkpoint inhibitors may have particular relevance in these cancers.
However, a patient whose stomach cancer has recurred after already receiving immunotherapy needs a different discussion. The treatment history matters, and an oncologist should determine whether another immune-based treatment is supported by the evidence for that particular situation.
What About CLDN18.2-Targeted Treatment?
CLDN18.2 is one of the newer biomarkers attracting significant attention in gastric cancer.
Although this is a first-line indication rather than a general treatment for recurrence, it demonstrates why CLDN18.2 testing has become increasingly relevant.
For a patient whose cancer has returned after previous treatment, the question may be whether CLDN18.2-targeted treatment, a clinical trial or another therapy is appropriate based on the patient's previous treatment and current disease.
Is CAR-T Therapy a Medication for Recurrent Stomach Cancer?
CAR-T is different from conventional medication. It is a cellular therapy in which a patient's T cells are collected and genetically modified to recognize a cancer target.
China has become particularly important in this area.
In 2026, China approved satricabtagene autoleucel (satri-cel/CT041) for a specific group of patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma after at least two prior lines of treatment.
This does not mean CAR-T is appropriate for everyone with recurrent stomach cancer. Eligibility depends on the tumor's CLDN18.2 status, HER2 status, previous treatment and other medical criteria.
Clinical research has also continued around CLDN18.2-directed CAR-T therapies and other cellular approaches. For an international patient, it is important to distinguish between an approved treatment and a clinical trial.
Why Should Medication Choices Be Based on Biomarkers?
Imagine two patients who both have recurrent gastric cancer.
One has a HER2-positive tumor. Another has a CLDN18.2-positive, HER2-negative tumor. A third may have MSI-H/dMMR disease.
Although all three have "recurrent stomach cancer," the treatment conversation may be completely different.
This is why it is worth asking whether the pathology has been tested for:
HER2
PD-L1
MSI/MMR
CLDN18.2
Other potentially actionable molecular alterations where appropriate
Testing can help prevent the treatment discussion from becoming simply, "What chemotherapy should we try next?"
Instead, the question becomes: "What does this particular cancer give us to target?"
What if Approved Medications are No Longer Working?
This is often when patients begin looking beyond their home country.
If several standard treatments have already been used, your oncologist may discuss another approved treatment, a clinical trial or a treatment available through a different regulatory pathway.
China is particularly relevant to some patients because of its expanding gastric cancer research and cellular-therapy programs. But travelling internationally should come after medical assessment, not instead of it.
Before travelling, ask the treating center:
What exact treatment is being proposed?
Is it commercially approved or investigational?
What biomarker makes me eligible?
How many previous treatment lines are required?
What evidence supports the treatment?
What are the major risks?
What happens if I am found not to qualify?
These questions can prevent a family from travelling thousands of kilometres for a treatment that ultimately is not appropriate.
How ChinaCureLink Can Help International Patients with Recurrent Stomach Cancer
ChinaCureLink helps international patients organize their medical records and explore treatment pathways at Chinese hospitals.
For recurrent stomach cancer, this can include reviewing pathology, imaging, biomarker results and previous treatment history before approaching an appropriate hospital.
If a patient is interested in an advanced treatment such as a CLDN18.2-directed therapy or CAR-T, the hospital's medical team must determine whether the patient meets the relevant eligibility criteria.
ChinaCureLink can then assist with communication, documentation, hospital coordination and the practical logistics involved in international treatment.
The goal is not simply to find a medication that exists in China. It is to determine whether there is a medically relevant treatment pathway for that particular patient.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
FAQ: Medications for Stomach Cancer Recurrence
What Medications are Used for Recurrent Stomach Cancer?
Treatment may include chemotherapy, targeted therapies and immunotherapy. Examples include paclitaxel, irinotecan, ramucirumab, trastuzumab deruxtecan and pembrolizumab in specific approved settings. The appropriate medication depends on previous treatment, tumor biomarkers and the extent of recurrence.
Is Ramucirumab Approved for Recurrent Gastric Cancer?
Yes. Ramucirumab is approved in the United States for advanced or metastatic gastric or GEJ adenocarcinoma that has progressed during or after prior fluoropyrimidine- or platinum-containing chemotherapy, both as monotherapy and in combination with paclitaxel.
Can Trastuzumab Deruxtecan Treat Recurrent Stomach Cancer?
Trastuzumab deruxtecan is FDA-approved for adults with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma after a prior trastuzumab-based regimen. It is therefore an important option for selected patients with HER2-positive recurrent or advanced disease.
Should Recurrent Stomach Cancer Be Tested for CLDN18.2?
CLDN18.2 testing can be important because it identifies patients who may qualify for specific targeted treatments and, in some settings, newer cellular therapies. Zolbetuximab is FDA-approved for a defined first-line CLDN18.2-positive, HER2-negative gastric/GEJ population.
Is CAR-T Approved for Recurrent Stomach Cancer in China?
China has approved satri-cel for a specific population with CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma after at least two prior lines of treatment. It is not a general treatment for every patient whose stomach cancer has returned.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
References
National Cancer Institute — Gastric Cancer Treatment (PDQ®). NCI Gastric Cancer Treatment
U.S. FDA — Ramucirumab (Cyramza) approval information. FDA Ramucirumab Approval Information
U.S. FDA — FDA approves trastuzumab deruxtecan for HER2-positive gastric adenocarcinomas. FDA Trastuzumab Deruxtecan Approval
U.S. FDA — FDA approves zolbetuximab with chemotherapy for gastric or GEJ adenocarcinoma.
U.S. FDA — FDA approves pembrolizumab for HER2-positive gastric/GEJ adenocarcinoma expressing PD-L1. FDA Pembrolizumab Approval